The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling

References

• Cohn-Hokke PE, Elting MW, Pijnenburg YA, Swieten JC. Genetics of dementia: Update and guidelines for the clinician. Am J Med Genet. 2012;159 B:628–643.
   Google Scholar
• Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med. 2017;19:267–274.
   Google Scholar
• Turner MR, Al-Chalabi A, Chio A, Hardiman O, Kiernan MC, Rohrer JD, et al. Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry. 2017;88:1042–1044.
   Google Scholar
• Wagner KN, Allain DC, Nagaraja HN, Allain DC, Roggenbuck J, Quick A, et al. Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing. Mol Genet Genomic Med. 2018;6:224–229.
   Google Scholar
• Wagner KN, Nagaraja H, Allain DC, Quick A, Kolb S, Roggenbuck J, et al. Patients with amyotrophic lateral sclerosis have high interest in and limited access to genetic testing. J Genet Counsel. 2017; 26: 604–611.
   Google Scholar
• Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A, et al. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:497–505.
   Google Scholar
• Stewart H, Rutherford NJ, Briemberg H, Krieger C, Cashman N, Fabros M, et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol. 2012;123:409–417.
   Google Scholar
• Ly CV, Miller TM. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Current Opinion in Neurology. 2018;31:648–654.
   Google Scholar
• Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535–550.
   Google Scholar
• Crook A, Williams K, Adams L, Blair I, Rowe DB. Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counseling considerations. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:475–485.
   Google Scholar
• Resta R, Biesecker BB, Bennett RL, Blum S, Estabrooks Hahn S, Strecker MN, et al. A new definition of genetic counseling: National Society of Genetic Counselors’ Task Force Report. J Genet Counsel. 2006;15:77–83.
   Google Scholar
• Human Genetics Society of Australasia. Guideline: Process of Genetic Counselling. Australia: Human Genetics Society of Australasia; 2015. Contract No.: 2012GL02.
   Google Scholar
• Chiò A, Battistini S, Calvo A, Caponnetto C, Conforti FL, Corbo M, et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry. 2014;85:478–485.
   Google Scholar
• Fong JC, Karydas AM, Goldman JS. Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion. Alzheimers Res Ther. 2012;4:27.
   Google Scholar
• Akimoto C, Volk AE, van Blitterswijk M, Van den Broeck M, Leblond CS, Lumbroso S, et al. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet. 2014;51:419–424.
   Google Scholar
• Fanos JH, Gronka S, Wuu J, Stanislaw C, Andersen PM, Benatar M, et al. Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis. Genet Med. 2011;13:342–348.
   Google Scholar
• Hartzfeld DEH, Siddique N, Victorson D, O’Neill S, Kinsley L, Siddique T, et al. Reproductive decision-making among individuals at risk for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:114–119.
   Google Scholar
• Molinuevo JL, Pintor L, Peri JM, Lleó A, Oliva R, Marcos T, et al. Emotional reactions to predictive testing in Alzheimer’s disease and other inherited dementias. Am J Alzheimers Dis Other Demen. 2005;20:233–238.
   Google Scholar
• Fanos JH, Gelinas DF, Miller RG. “You have shown me my end”: attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosis. Am J Med Genet. 2004;129A:248–253.
   Google Scholar
• Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol. 2001;58:1828–1831.
   Google Scholar
• Riedijk SR, Niermeijer MFN, Dooijes D, Tibben A. A decade of genetic counseling in frontotemporal dementia affected families: few counseling requests and much familial opposition to testing. J Genet Counsel. 2009;18:350–356.
   Google Scholar
• van der Meer LB, van Duijn E, Giltay EJ, Tibben A. Do attachment style and emotion regulation strategies indicate distress in predictive testing? J Genet Counsel. 2015;24:862–871.
   Google Scholar
• Almqvist EW, Bloch M, Brinkman R, Craufurd D, Hayden MR. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Gen. 1999;64:1293–1304.
   Google Scholar
• Meisler MH, Grant AE, Jones JM, Lenk GM, He F, Todd PK, et al. C9ORF72 expansion in a family with bipolar disorder. Bipolar Disord. 2013;15:326–332.
   Google Scholar
• Synofzik M, Biskup S, Leyhe T, Reimold M, Fallgatter AJ, Metzger F, et al. Suicide attempt as the presenting symptom of C9orf72 dementia. AJP. 2012;169:1211–1213.
   Google Scholar
• Byrne S, Heverin M, Elamin M, Bede P, Lynch C, Kenna K, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: A population-based case-control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann Neurol. 2013;74:699–708.
   Google Scholar
• Nance MA. Genetic counseling and testing for Huntington’s disease: a historical review. Am J Med Genet. 2017;174:75–92.
   Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245–256.
   Google Scholar
• Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A Hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–268.
   Google Scholar
• Cleary EM, Pal S, Azam T, Moore DJ, Swingler R, Gorrie G, et al. Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions. Mol Cell Probes. 2016;30:218–224.
   Google Scholar
• Cruts M, Engelborghs S, van der Zee J, Van Broeckhoven C, et al. C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 2015.
   Google Scholar
• Woollacott IOC, Mead S. The C9ORF72 expansion mutation: gene structure, phenotypic and diagnostic issues. Acta Neuropathol. 2014;127:319–332.
   Google Scholar
• Fratta P, Polke JM, Newcombe J, Mizielinska S, Lashley T, Poulter M, et al. Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiol Aging. 2015;36:546.e1–546.e7.
   Google Scholar
• Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, De Bleecker J, et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol Psychiatry. 2016;21:1112–1124.
   Google Scholar
• Rollinson S, Bennion Callister J, Young K, Ryan SJ, Druyeh R, Rohrer JD, et al. A small deletion in C9orf72 hides a proportion of expansion carriers in FTLD. Neurobiol Aging. 2015;36:1601.e1–1601.e5.
   Google Scholar
• Dolzhenko E, et al. Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome Res. 2017;27:1895–1903.
   Google Scholar
• Suh E, Grando K, Van Deerlin VM. Validation of a long-read PCR assay for sensitive detection and sizing of C9orf72 hexanucleotide repeat expansions. J Mol Diagn. 2018;20:871–882.
   Google Scholar
• Xi Z, Zhang M, Bruni AC, Maletta RG, Colao R, Fratta P, et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol. 2015;129:715–727.
   Google Scholar
• Ng AS, Tan EK. Intermediate C9orf72 alleles in neurological disorders: does size really matter? J Med Genet. 2017;54:591–597.
   Google Scholar
• Gomez-Tortosa E, Gallego J, Guerrero-Lopez R, Marcos A, Gil-Neciga E, Sainz MJ, et al. C9ORF72 hexanucleotide expansions of 20-22 repeats are associated with frontotemporal deterioration. Neurology. 2013;80:366–370.
   Google Scholar
• Byrne S, Heverin M, Elamin M, Walsh C, Hardiman O. Intermediate repeat expansion length in C9orf72 may be pathological in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:148–150.
   Google Scholar
• van d. Z, J, et al. A Pan-European Study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat. 2013;34:363–373.
   Google Scholar
• Xi Z, Yunusova Y, van Blitterswijk M, Dib S, Ghani M, Moreno D, et al. Identical twins with the C9orf72 repeat expansion are discordant for ALS. Neurology. 2014;83:1476–1478.
   Google Scholar
• Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chiò A, Traynor BJ, et al. Age-related penetrance of the C9orf72 repeat expansion. Sci Rep. 2017;7:2116.
   Google Scholar
• Majounie E, Renton AE, Mok K, Dopper EGP, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323–330.
   Google Scholar
• Van Blitterswijk M, DeJesus-Hernandez M, Rademakers R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Curr Opin Neurol. 2012;25:689–700.
   Google Scholar
• Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet. 2013;92:345–53.
   Google Scholar
• Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17:17–23.
   Google Scholar
• van Blitterswijk M, van Es MA, Hennekam EAM, Dooijes D, van Rheenen W, Medic J, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:3776–3784.
   Google Scholar
• Chio A, Mazzini L, Alfonso D, Corrado L, Canosa A, Moglia C, et al. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology. 2018;91:e635–e642.
   Google Scholar
• Giannoccaro MP, Bartoletti-Stella A, Piras S, Pession A, De Massis P, Oppi F, et al. Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature. J Neurol. 2017;264:1426–1433.
   Google Scholar
• Dekker AM, Seelen M, van Doormaal PTC, van Rheenen W, Bothof RJP, van Riessen T, et al. Large-scale screening in sporadic amyotrophic lateral sclerosis identifies genetic modifiers in C9orf72 repeat carriers. Neurobiol Aging. 2016;39:220.e9–220.e15.
   Google Scholar
• Barbier M, Camuzat A, Houot M, Clot F, Caroppo P, Fournier C, et al. Factors influencing the age at onset in familial frontotemporal lobar dementia: important weight of genetics. Neurol Genet. 2017;3:e203.
   Google Scholar
• McMillan CT, Russ J, Wood EM, Irwin DJ, Grossman M, McCluskey L, et al. C9orf72 promoter hypermethylation is neuroprotective: neuroimaging and neuropathologic evidence. Neurology. 2015;84:1622–1630.
   Google Scholar
• Lesage S, Le Ber I, Condroyer C, Broussolle E, Gabelle A, Thobois S, et al. C9orf72 repeat expansions are a rare genetic cause of Parkinsonism. Brain. 2013;136:385–391.
   Google Scholar
• Devenney EM, Ahmed RM, Halliday G, Piguet O, Kiernan MC, Hodges JR, et al. Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members. Neurology. 2018;91:e1498.
   Google Scholar
• Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8:322ra9.
   Google Scholar
• Vajda A, McLaughlin RL, Heverin M, Thorpe O, Abrahams S, Al-Chalabi A, et al. Genetic testing in ALS: a survey of current practices. Neurology 2017;88:991–999.
   Google Scholar
• National Association of Testing Authorities, A. About Accreditation. 2018 [cited 2018 10/09/2018]; Available from: https://www.nata.com.au/about-nata/about-accreditation.
   Google Scholar
• McCann EP, Williams KL, Fifita JA, Tarr IS, O’Connor J, Rowe DB, et al. The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet. 2017;92:259–266.
   Google Scholar